



FOR IMMEDIATE RELEASE

Sun Pharma reports Q1FY26 results

*Q1 Gross Sales at Rs. 137,861 million up 10.1% YoY
Q1 Adjusted Net Profit at Rs. 29,961 million, up 5.7% YoY*

Mumbai, July 31, 2025: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) reported financials for the first quarter ending June 30th, 2025.

Highlights of Q1FY26 consolidated financials*

- Gross sales at Rs. 137,861 million, growth of 10.1%
- India formulation sales at Rs. 47,211 million, up 13.9%
- US formulation sales at US\$ 473 million, up 1.4%
- Global Innovative Medicines** sales at US\$ 311 million, up 16.9%, accounting for 19.3% of Q1FY26 sales
- Emerging Markets formulation sales at US\$ 298 million, up 5.1%
- Rest of World formulation sales at US\$ 219 million, up 15.5%
- R&D investments at Rs. 9,029 million or 6.5% of sales compared to Rs. 7,940 million for Q1FY25
- EBITDA at Rs. 43,017 million (including other operating revenues), up 19.2%, with resulting EBITDA margin of 31.1%
- Profit before exceptional items and tax was Rs 39,908 million up 16.6%
- Adjusted net profit (excluding the exceptional items) for Q1FY26 was Rs. 29,961 million, up 5.7%. Reported net profit for Q1FY26 was Rs. 22,786 million compared to Rs. 28,356 million during Q1FY25

**Growth measured vs same period last financial year*

*** "Specialty" business renamed as "Innovative Medicines"*

Dilip Shanghvi, Chairman and Managing Director of the Company, said, "Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business."

India Formulations

Formulation sales in India were Rs. 47,211 million, up by 13.9%. India Formulation sales accounted for 34.2% of total consolidated sales for the quarter.

Sun Pharma is ranked No. 1 and market share has increased from 8.0% to 8.3% in the over Rs. 2,302 Billion Indian pharmaceutical market as per AIOCD/ Pharमारack MAT June-2025 report. As per SMSRC (Mar-Jun 2025) report, Sun Pharma is No.1 ranked by prescriptions with 13 different doctor categories. For Q1FY26, the company launched 5 new products in the Indian market.

US Formulations

Formulation sales in the US were US\$ 473 million; accounting for over 29.3% of total consolidated sales.

Innovative Medicines

Global Innovative Medicines sales were US\$ 311 million for Q1FY26, up 16.9% over Q1 last year and accounted for 19.3% of total consolidated sales for the quarter.

Emerging Markets (EM) Formulations

Emerging Market formulations sales were US\$ 298 million for Q1FY26, up by 5.1% and accounted for 18.5% of total consolidated sales.

Rest of World (ROW) Formulations

Formulation sales in Rest of World (RoW) markets were US\$ 219 million for Q1FY26, up by 15.5% and accounted for 13.6% of total consolidated sales for the quarter.

Active Pharmaceutical Ingredients (API)

For Q1FY26, external sales of API were at Rs. 5,404 million, up by 9.3%. Our API portfolio supports our formulation business and API customers across geographies.

R&D Update

Sun Pharma's R&D efforts span across both innovative and generic businesses and the company continues to invest in building the pipeline for various markets. Sun's innovative R&D pipeline includes six novel entities in clinical stage. Sun has a comprehensive product offering in the US market consisting of approved ANDAs for 542 products while filings for 119 ANDAs await US FDA approval, including 33 tentative approvals. Additionally, the portfolio includes 57 approved NDAs while 13 NDAs await US FDA approval. For the quarter, 2 ANDA were filed and 1 ANDA approval was received.

Innovative Medicines Pipeline

Candidate	Indication	Current phase	Next milestone
Unloxyt	metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC	Approved in the US	Launch
Ilumya	psoriatic arthritis	Phase 3 completed	Regulatory filing
Fibromun	soft tissue sarcoma	Phase 3	Regulatory filing
	Glioblastoma	Phase 2	Regulatory filing
GL0034	type 2 diabetes	Phase 1 completed	Phase 2 to start during H2CY25
Nidleg TM (EU, ANZ rights with Sun)	melanoma and non-melanoma skin cancers	Phase 3 completed. Original application to EMA withdrawn	Filing with EMA
MM-II	pain in osteoarthritis	Phase 2 completed	To enter partnership for commercialization

Sales and R&D snapshot

Particulars	Quarter ended			Year ended
	30.06.2025	31.03.2025	30.06.2024	31.03.2025
India Formulations	47,211.0	42,129.6	41,445.1	169,230.0
US Formulations	40,452.1	40,204.1	38,894.4	162,402.8
EM Formulations	25,531.4	22,561.2	23,695.2	94,159.8
RoW Formulations	18,735.9	17,339.7	15,813.6	71,626.0
Total Formulations	131,930.4	122,234.6	119,848.3	497,418.6
Bulk (API)	5,403.7	5,330.3	4,945.7	21,292.2
Others	526.6	590.9	451.1	1,701.7
Total Sales	137,860.7	128,155.8	125,245.1	520,412.5
Total R&D Expenditure	9,028.6	8,165.5	7,939.7	32,484.4
Capital	187.6	261.5	177.8	942.5
Revenue	8,841.0	7,904.0	7,761.9	31,541.9
Exchange Rates : \$ 1 = ₹	85.56	86.62	83.42	

Earnings Call (06.30 pm IST, July 31, 2025)

The Company will host earnings call at 06.30 pm IST on July 31, 2025, where senior management will discuss the Company's performance and answer questions from participants. This call will be accessible through an audio dial-in and a web-cast.

Audio conference Participants can dial-in on the numbers below
Universal number: +91 22 6629 0049
+91 22 7194 5729

Pre-registration details Click here [DiamondPassRegistration](#)

Web-cast More details will be provided through our website, www.sunpharma.com

To participate in the audio call, please dial the numbers provided above five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. The transcript of the event will be available at www.sunpharma.com. The playback will be available for a few days.

Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Sun Pharmaceutical Industries Limited
SUN HOUSE, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's leading specialty generics company with a presence in Innovative Medicines, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun's high growth Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 20% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. "For further information, please visit www.sunpharma.com and follow us on LinkedIn & X (Formerly Twitter)."

Contacts:

Investors:

Dr. Abhishek Sharma
Tel +91 22 4324 4324, Xtn 2929
Tel Direct +91 22 4324 2929
Mobile +91 98196 86016
E mail abhi.sharma@sunpharma.com

Media:

Gaurav Chugh
Tel +91 22 4324 4324, Xtn 5373
Tel Direct +91 22 4324 5373
Mobile +91 98104 71414
E mail gaurav.chugh@sunpharma.com